Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

Andre Esteva, PhD, is an AI scientist, entrepreneur, and CEO of ArteraAI, revolutionizing cancer therapy through personalized diagnostics. A globally recognized ...

National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...

The Galway-based company is set for a huge expansion ...

A novel long-term prediction model showed promise at estimating the risk for dying of prostate cancer, an analysis published ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Doctors began testing PSA levels in the 1980s to monitor diagnosed cancers. By the early 1990s, researchers promoted it for ...

GRENOBLE, France and PRINCETON, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a leader and innovator in MRI-ultrasound fusion guidance for prostate ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

A research team at the University of Würzburg has, for the first time, uncovered how E. coli bacteria sneak into the prostate ...

Cribriform-negative disease had a low metastasis rate unaffected by treatment. After radiation therapy with neoadjuvant ADT group, men with cribriform-positive disease had the same metastasis rate as ...